

18 February 2014

NEW GLOBAL SUPPLY AGREEMENT FOR RESEARCH ENDOMICROSCOPY

Optiscan is pleased to announce it has executed an exclusive OEM supply agreement with UK based MR Solutions for its second generation research endomicroscopy system or the FIVE-2.

MR Solutions is the leading developer and manufacturer of the world's first range of commercial, pre-clinical, 3T (3 Tesla) and cryogen free, benchtop MRI systems. The systems are specifically designed for mice and rat studies, molecular imaging, multi-nuclear and multi-modality applications. The systems' revolutionary cryogen-free superconducting magnet technology complements and operates in close proximity to other imaging modalities, including SPECT, PET and optical. The MRI systems offer superior soft tissue contrast and high spatial resolution.

MR Solutions has sales and marketing staff based in the UK, France, the USA, Canada and Australia. MR Solutions has a significant presence at all the major trade shows in the field of pre-clinical imaging. MR Solutions has customers in China, Taiwan, Japan, Korea, Russia, Spain, France, Germany, Belgium, UK, USA and Canada.

This is an exciting opportunity for Optiscan. Joining forces with a highly relevant and complementary partner in MR Solutions will allow the Company to bring its second generation technology alive in the research endomicroscopy market. Substantial opportunities exist within this market both in terms of unit sales and the flow on benefits of translational research into the clinical arena. In excess of 1,000 relevant institutions have been identified as high priority research sales targets with activity to commence forthwith.

About Optiscan

Optiscan is a global leader in microscopic imaging technologies for medical markets. Optiscan's unique and patented technologies enable high-powered microscopes to be miniaturised and used inside the body. The technology enables microscopic imaging of up to 1000 times magnification to be achieved. Doctors can use the technology to instantly see cellular level details of tissue without the requirement to surgically remove tissue (biopsy).

Further information:

Gus Holt, Chairman Tel (613) 9538 3347 GusH@optiscan.com Bruce Andrew, CFO Tel (613) 9538 3398 brucea@optiscan.com